Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 34,809 Shares of Stock

Key Points

• CFO Vaseem Mahboob sold 34,809 Kestra shares at an average $30.04, worth approximately $1.05 million, reducing his direct holdings by 36.48% to 60,609 shares. He also reported several additional sales in recent months.
• KMTS shares rose 2.5% to $30.61, near their 52-week high of $31.04, despite the company’s latest quarterly loss of $0.75 per share, which missed analyst expectations.
• Analyst sentiment remains a “Moderate Buy”, with a consensus price target of $29.00; five analysts rate the stock Buy, two Hold, and one Sell.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $30.04, for a total transaction of $1,045,662.36. Following the sale, the chief financial officer directly owned 60,609 shares in the company, valued at $1,820,694.36. The trade was a 36.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Vaseem Mahboob also recently made the following trade(s):

• On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44.
• On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.60, for a total transaction of $146,512.80.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total value of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total value of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.

Kestra Medical Technologies Stock Up 2.5%

KMTS traded up $0.74 during midday trading on Thursday, reaching $30.61. The company's stock had a trading volume of 470,598 shares, compared to its average volume of 351,886. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -11.46 and a beta of 0.51. The stock's 50-day moving average is $26.59 and its 200-day moving average is $23.76. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $31.04.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million for the quarter. As a group, research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analysts Set New Price Targets

KMTS has been the subject of several recent analyst reports. Wall Street Zen cut shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an "overweight" rating and a $30.00 price target for the company. Weiss Ratings upgraded shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, September 16th. BTIG Research reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.00.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Kestra Medical Technologies in the third quarter worth about $353,000. Sterling Capital Management LLC increased its position in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after purchasing an additional 784 shares during the last quarter. Corient Private Wealth LP lifted its stake in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after purchasing an additional 44,839 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after buying an additional 7,844 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock worth $1,844,000 after buying an additional 5,731 shares during the last quarter.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.